jueves, 2 de octubre de 2025

A first-of-its-kind therapy offers a new path for hard-to-treat airway disorder Papzimeos is the first FDA-approved therapy for recurrent respiratory papillomatosis, a rare HPV-driven disease that has long forced patients into repeated surgeries.

https://www.drugdiscoverynews.com/a-first-of-its-kind-therapy-offers-a-new-path-for-hard-to-treat-airway-disorders-16696

No hay comentarios:

Publicar un comentario